|
Kolltan licenses antibodies from founder
Hartford Business The so-called anti-KIT receptor tyrosine kinase antibodies were developed in the labs of Joseph Schlessinger at Yale University — a Kolltan founder — and Sachdev Sidu, a geneticist at the University of Toronto and Kolltan adviser. Terms of the deal … |
Obinutuzumab routs rituximab in older chronic lymphocytic leukemia patients – The Oncology Report
This is Local London |
Obinutuzumab routs rituximab in older chronic lymphocytic leukemia patients
The Oncology Report In the CLL11 study of older chronic lymphocytic leukemia (CLL) patients with coexisting medical problems, obinutuzumab (Gazyva) pushed the overall response rate to 78%, compared with 65% with rituximab (Rituxan) (P less than .0001). Both drugs were … Obinutuzumab Tops Rituximab in CLL TrialCancer Network Dr. Goede on Obinutuzumab Versus Rituximab in CLLOncLive New Drug Combo Potentially ‘Practice Changing’ in CLLMedscape Healio –PR Newswire (press release) all 15 news articles » |
NKT Therapeutics' Identifies Novel anti-iNKT Antibodies for Depleting or … – PR Newswire (press release)
|
NKT Therapeutics’ Identifies Novel anti-iNKT Antibodies for Depleting or …
PR Newswire (press release) WALTHAM, Mass., Dec. 9, 2013 /PRNewswire/ — NKT Therapeutics (NKTT) today presented research results with NKT14 and NKT14m, monoclonal antibodies designed to deplete (NKT14) or activate (NKT14m) murine iNKT cells. The results from these … |
Janssen Oncology Data to be Presented at 2013 American Society of … – FiercePharma
|
Janssen Oncology Data to be Presented at 2013 American Society of …
FiercePharma Combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP): updated results from a phase 1b study in treatment-naïve patients with CD20-positive B-cell non-Hodgkin’s lymphoma (NHL). (Abstract 852). |
Kolltan Pharmaceuticals licenses anti-KIT antibodies from University of Toronto – Pharmaceutical Business Review
Kolltan Pharmaceuticals licenses anti-KIT antibodies from University of TorontoPharmaceutical Business ReviewKolltan Pharmaceuticals, a privately held biopharmaceutical company, has signed a licensing agreement with the University of Toronto for anti-K…
Is Uterus Transplant Allowed? – Onislam.net
Is Uterus Transplant Allowed?Onislam.netUterus transplant is permitted according to most scholars and Fiqh councils in many places. This opinion is built on the notion that the uterus is only a container for the baby. The uterus does not transfer any g…
Interim Phase IIa Results for Spiegelmer ® Olaptesed Pegol (NOX-A12) in CLL … – Business Wire (press release)
|
Interim Phase IIa Results for Spiegelmer ® Olaptesed Pegol (NOX-A12) in CLL …
Business Wire (press release) In the first study, olaptesed was administered to relapsed chronic lymphocytic leukemia (CLL) patients in combination with bendamustine and rituximab. In the second study, olaptesed was combined with bortezomib and dexamethasone in patients with … |
Global qPCR and dPCR Instrumentation Industry – Sacramento Bee
|
Global qPCR and dPCR Instrumentation Industry
Sacramento Bee … Technologies and Quidel Secure US FDA Approval for Marketing RT-PCR Instruments II-48 Life Technologies Obtains US FDA Approval for 3500 Dx Genetic Analyzers and SeCore® HLA Typing Kit II-48 Bio-Rad Unveils iTaq Universal Supermixes II-49. |
Now There Are Six: Banner Health adds to their Accredited Heart Failure … – eReleases (press release)
|
Now There Are Six: Banner Health adds to their Accredited Heart Failure …
eReleases (press release) PHOENIX, Dec. 9, 2013 /PRNewswire/ — The Healthcare Accreditation Colloquium announced that Banner Baywood and Banner Del E. Webb medical centers have been named Accredited Heart Failure Centers. This continues a unique quality initiative that … |
Needed: More diverse and younger bone marrow donors – NBC Latino
|
Needed: More diverse and younger bone marrow donors
NBC Latino HLA typing (or tissue typing) is used to match patients and donors for marrow or umbilical cord blood transplants, da Silva explains. “HLA are proteins—or markers—found on most cells in the body. A patient’s immune system uses these markers to … |